PCM
GBT

Penserra Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Penserra Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,430
Closed -$36K – 1628
2021
Q3 		$36K Buy
1,430
+15
+1% +$441 ﹤0.01% 1148
2021
Q2 		$49K Buy
1,415
+5
+0.4% +$195 ﹤0.01% 1007
2021
Q1 		$57K Sell
1,410
-15
-1% -$689 ﹤0.01% 798
2020
Q4 		$61K Buy
1,425
+899
+171% +$44.3K ﹤0.01% 665
2020
Q3 		$29K Buy
+526
New +$33.4K ﹤0.01% 698

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Penserra Capital Management's GBT Position: Q4 2021 in Review

Penserra Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2021, closing a stake of 1,430 shares — an estimated $36K sold.

Penserra Capital Management first reported a position in GBT in Q3 2020 and held it in 5 quarters. The position peaked at $61K in Q4 2020. 206 funds tracked by Wall St. Rank hold GBT as of Q4 2021.

  • Penserra Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,430 Global Blood Therapeutics, Inc. shares in Q4 2021, an estimated $36K.
  • Penserra Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Global Blood Therapeutics, Inc. position peaked at $61K in Q4 2020.
  • 206 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.